Intravesical delivery of rapamycin via folate-modified liposomes dispersed in thermo-reversible hydrogel

References

• Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2010;105:300–308. doi:10.1111/j.1464-410X.2009.09076.x19912200
   PubMed Web of Science ®Google Scholar
• Jensen TK, Holt P, Gerke O, et al. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol. 2011;45:122–128. doi:10.3109/00365599.2010.54467221231796
   PubMed Web of Science ®Google Scholar
• Oliveira MB, Villa Nova M, Bruschi ML. A review of recent developments on micro/nanostructured pharmaceutical systems for intravesical therapy of the bladder cancer. Pharm Dev Technol. 2018;23:1–12. doi:10.1080/10837450.2017.131244128347192
   PubMed Web of Science ®Google Scholar
• Mattioli F, Curotto A, Manfredi V, et al. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. Anticancer Res. 2005;25:2493–2496.16080482
   PubMed Web of Science ®Google Scholar
• Malmstro¨m. Intravesical therapy of superficial bladder cancer. Crit Rev Oncol Hematol. 2003;47:109–126. doi:10.1016/S1040-8428(03)00075-112900005
   PubMed Web of Science ®Google Scholar
• Packiam VT, Johnson SC, Steinberg GD. Non-muscle-invasive bladder cancer: intravesical treatments beyond Bacille Calmette-Guérin. Cancer. 2017;123:390–400. doi:10.1002/cncr.v123.328112819
   PubMedGoogle Scholar
• Guduru SKR, Arya P. Synthesis and biological evaluation of rapamycin-derived, next generation small molecules. Medchemcomm. 2017;9:27–43. doi:10.1039/C7MD00474E30108899
   PubMedGoogle Scholar
• Wan X 1, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007;12:1007–1018. doi:10.1634/theoncologist.12-8-100717766661
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5:0139–0151. doi:10.1371/journal.pmed.0050008
   Web of Science ®Google Scholar
• Rouf MA, Vural I, Renoir JM, et al. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J Liposome Res. 2009;19:322–331. doi:10.3109/0898210090296304319863167
   PubMed Web of Science ®Google Scholar
• Seager CM, Puzio-Kuter AM, Patel T, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila). 2009;2:1008–1014. doi:10.1158/1940-6207.CAPR-09-016919952358
   PubMed Web of Science ®Google Scholar
• Preetham AC, Satish CS. Formulation of a poorly water-soluble drug sirolimus in solid dispersions to improve dissolution. J Dispers Sci Technol. 2011;32:778–783. doi:10.1080/01932691.2010.488129
   Web of Science ®Google Scholar
• GuhaSarkar S, Banerjee R. Intravesical drug delivery: challenges, current status, opportunities and novel strategies. J Control Release. 2010;148:147–159. doi:10.1016/j.jconrel.2010.08.03120831887
   PubMed Web of Science ®Google Scholar
• Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR, Heston WD. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther. 2000;7:844–851. doi:10.1038/sj.gt.330107610845722
   PubMed Web of Science ®Google Scholar
• Vila-Caballer M, Codolo G, Munari F, et al. A pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine)-decorated liposome system for protein delivery: an application for bladder cancer treatment. J Control Release. 2016;238:31–42. doi:10.1016/j.jconrel.2016.07.02427444816
   PubMed Web of Science ®Google Scholar
• Miyazaki J, Nishiyama H, Yano I, et al. The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res. 2011;31:2065–2071.21737624
   PubMed Web of Science ®Google Scholar
• Kim CH, Lee SG, Kang MJ, Lee SK, Choi YW. Surface modification of lipid-based nanocarriers for cancer cell-specific drug targeting. J Pharm Investig. 2017;47:203–227. doi:10.1007/s40005-017-0329-5
   Google Scholar
• Gupta B, Yong CS, Kim JO. Solid matrix-based lipid nanoplatforms as carriers for combinational therapeutics in cancer. J Pharm Investig. 2017;47:461–473. doi:10.1007/s40005-017-0337-5
   Google Scholar
• Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release. 2003;92:49–67.14499185
   PubMed Web of Science ®Google Scholar
• Kang MH, Yoo HJ, Kwon YH, et al. Design of Multifunctional Liposomal Nanocarriers for Folate Receptor-Specific Intracellular Drug Delivery. Mol Pharm. 2015;12:4200–4213.26544061
   PubMed Web of Science ®Google Scholar
• Kolawole OM, Lau WM, Mostafid H, Khutoryanskiy VV. Advances in intravesical drug delivery systems to treat bladder cancer. Int J Pharm. 2017;532:105–117. doi:10.1016/j.ijpharm.2017.08.12028867449
   PubMedGoogle Scholar
• Hadaschik BA. ter Borg MG, Jackson J, et al. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU Int. 2008;101:1347–1355. doi:10.1111/j.1464-410X.2008.07571.x18384637
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim SR, Yoon HY, et al. Poloxamer 407 Hydrogels for Intravesical Instillation to Mouse Bladder: gel-Forming Capacity and Retention Performance. Korean J Urol Oncol. 2017;15:178–186. doi:10.22465/kjuo.2017.15.3.178
   Google Scholar
• Zhang L, Parsons DL, Navarre C, et al. Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release. 2002;85:73–81. doi:10.1016/S0168-3659(02)00273-012480313
   PubMed Web of Science ®Google Scholar
• Ju C, Sun J, Zi P, et al. Thermosensitive micelles-hydrogel hybrid system based on poloxamer 407 for localized delivery of paclitaxel. J Pharm Sci. 2013;102:2707–2717. doi:10.1002/jps.2364923839931
   PubMed Web of Science ®Google Scholar
• Wickremasinghe NC, Kumar VA, Hartgerink JD. Two-step self-assembly of liposome-multidomain peptide nanofiber hydrogel for time-controlled release. Biomacromolecules. 2014;15:3587–3595. doi:10.1021/bm500856c25308335
   PubMed Web of Science ®Google Scholar
• Majumder P, Baxa U, Walsh STR, Schneider JP. Design of a Multicompartment Hydrogel that Facilitates Time-Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma. Angew Chem. 2018;130:15260–15264. doi:10.1002/ange.201806483
   Google Scholar
• Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016;12:16071–16088. doi:10.1038/natrevmats.2016.71
   Google Scholar
• Jang MH, Kim CH, Yoon HY, et al. Steric stabilization of RIPL peptide-conjugated liposomes and in vitro assessment. J Pharm Investig. 2019;49:115–125. doi:10.1007/s40005-018-0392-6
   Google Scholar
• Sonali; Singh RP, Sharma G, et al. RGD-TPGS decorated theranostic liposomes for brain targeted delivery. Colloids Surf B Biointerfaces. 2016;147:129–141. doi:10.1016/j.colsurfb.2016.07.05827497076
   PubMed Web of Science ®Google Scholar
• Wu W, He Z, Zhang Z, Yu X, Song Z, Li X. Intravitreal injection of rapamycin-loaded polymeric micelles for inhibition of ocular inflammation in rat model. Int J Pharm. 2016;513:238–246. doi:10.1016/j.ijpharm.2016.09.01327609662
   PubMed Web of Science ®Google Scholar
• Whang YM, Park SI, Trenary IA. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. Oncogene. 2016;35:856–866. doi:10.1038/onc.2015.14026119936
   PubMed Web of Science ®Google Scholar
• Whang YM, Kim YH, Kim JS, Yoo YD. RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression. Cancer Res. 2005;65:3682–3690. doi:10.1158/0008-5472.CAN-04-455715867363
   PubMedGoogle Scholar
• Derakhshandeh K, Fashi M, Seifoleslami S. Thermosensitive pluronic hydrogel: prolonged injectable formulation for drug abuse. Drug Des Devel Ther. 2010;4:255–262. doi:10.2147/DDDT.S13289
   PubMed Web of Science ®Google Scholar
• Mao Y, Li X, Chen G, Wang S. Thermosensitive hydrogel system with paclitaxel liposomes used in localized drug delivery system for in situ treatment of tumor: better antitumor efficacy and lower toxicity. J Pharm Sci. 2016;105:194–204. doi:10.1002/jps.2469326580704
   PubMed Web of Science ®Google Scholar
• Kim SY, Kwon WA, Shin SP. Electrostatic interaction of tumor-targeting adenoviruses with aminoclay acquires enhanced infectivity to tumor cells inside the bladder and has better cytotoxic activity. Drug Deliv. 2018;25:49–58. doi:10.1080/10717544.2018.147496729224371
   PubMed Web of Science ®Google Scholar
• Decuzzi P, Godin B, Tanaka T, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release. 2010;141:320–327. doi:10.1016/j.jconrel.2009.09.00719874859
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015;200:138–157. doi:10.1016/j.jconrel.2014.12.03025545217
   PubMed Web of Science ®Google Scholar
• Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small. 2010;6:12–21. doi:10.1002/smll.20090115819844908
   PubMed Web of Science ®Google Scholar
• Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J. 1980;186:591–598. doi:10.1042/bj18605917378067
   PubMed Web of Science ®Google Scholar
• Yang T, Cui FD, Choi MK, et al. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv. 2007;14:301–308. doi:10.1080/1071754070160648317613018
   PubMed Web of Science ®Google Scholar
• Briuglia ML, Rotella C, McFarlane A, Lamprou DA. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv Transl Res. 2015;5:231–242. doi:10.1007/s13346-015-0247-x25787731
   PubMed Web of Science ®Google Scholar
• Vijayakumar MR, Kosuru R, Vuddanda PR, Singh SK, Singh S. Trans resveratrol loaded DSPE PEG 2000 coated liposomes: an evidence for prolonged systemic circulation and passive brain targeting. J Drug Deliv Sci Technol. 2016;33:125–135. doi:10.1016/j.jddst.2016.02.009
   Web of Science ®Google Scholar
• Roy B, Guha P, Bhattarai R, et al. Influence of lipid composition, pH, and temperature on physicochemical properties of liposomes with curcumin as model drug. J Oleo Sci. 2016;65:399–411. doi:10.5650/jos.ess1522827150333
   PubMed Web of Science ®Google Scholar
• Reddy JA, Low PS. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J Control Release. 2000;64:27–37. doi:10.1016/S0168-3659(99)00135-210640643
   PubMed Web of Science ®Google Scholar
• Shi G, Guo W, Stephenson SM, Lee RJ. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J Control Release. 2002;80:309–319. doi:10.1016/S0168-3659(02)00017-211943407
   PubMed Web of Science ®Google Scholar
• Poh S, Chelvam V, Ayala-López W, Putt KS, Low PS. Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases. Nanomedicine. 2018;14:1033–1043. doi:10.1016/j.nano.2018.01.00929410110
   PubMed Web of Science ®Google Scholar
• Li Q, Rao R, Vazzana J, et al. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. J Immunol. 2012;188:3080–3087. doi:10.4049/jimmunol.110336522379028
   PubMed Web of Science ®Google Scholar
• Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle. 2009;8:3831–3837. doi:10.4161/cc.8.23.1007019901542
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729–734. doi:10.1038/nrc197416915295
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22. doi:10.1016/j.ccr.2007.05.00817613433
   PubMed Web of Science ®Google Scholar
• Chiang GG, Abraham RT. Phosphorylation of Mammalian Target of Rapamycin (mTOR) at ser-2448 is mediated by p70S6 kinase. J Biol Chem. 2005;280:25485–25490. doi:10.1074/jbc.M50170720015899889
   PubMed Web of Science ®Google Scholar
• Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25:1895–1908. doi:10.1101/gad.1742011121937710
   PubMed Web of Science ®Google Scholar
• Wang W, Guan KL. AMP‐activated protein kinase and cancer. Acta Physiologica. 2009;196:55–63. doi:10.1111/j.1748-1716.2009.01980.x19243571
   PubMed Web of Science ®Google Scholar
• Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132. doi:10.1038/ncb215221258367
   PubMed Web of Science ®Google Scholar
• Egan DF, Shackelford DB, Mihaylova MM, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011;331:456–461. doi:10.1126/science.119637121205641
   PubMed Web of Science ®Google Scholar
• Wirth M, Joachim J, Tooze SA. Autophagosome formation–the role of ULK1 and Beclin1-PI3KC3 complexes in setting the stage. Semin Cancer Biol. 2013;23:301–309. doi:10.1016/j.semcancer.2013.05.00723727157
   PubMed Web of Science ®Google Scholar
• Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:256–262. doi:10.1016/S0092-8674(00)00117-3
   Web of Science ®Google Scholar
• Kirkin V, Lamark T, Sou Y-S, et al. A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. Mol Cell. 2009;33:505–516. doi:10.1016/j.molcel.2009.01.02019250911
   PubMed Web of Science ®Google Scholar
• Caramés B, Hasegawa A, Taniguchi N, Miyaki S, Blanco FJ, Lotz M. Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. Ann Rheum Dis. 2012;71:575–581. doi:10.1136/annrheumdis-2011-20055722084394
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Glickman MS 1, Bochner BH. The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol. 2014;11:153–162. doi:10.1038/nrurol.2014.1524492433
   PubMed Web of Science ®Google Scholar
• Nie S, Hsiao WL, Pan W, Yang Z. Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomedicine. 2011;6:151–166. doi:10.2147/IJN.S2564621499415
   PubMed Web of Science ®Google Scholar
• Matanović MR, Kristl J, Grabnar PA. Thermoresponsive polymers: insights into decisive hydrogel characteristics, mechanisms of gelation, and promising biomedical applications. Int J Pharm. 2014;472:262–275. doi:10.1016/j.ijpharm.2014.06.02924950367
   PubMed Web of Science ®Google Scholar
• Kristl J, Pecar S, Smid-Korbar J, Schara M. Molecular motion of drugs in hydrocolloids measured by electron paramagnetic resonance. Pharm Res. 1991;8:505–507.1651487
   PubMed Web of Science ®Google Scholar